ArchiveOctober 2015

Myelin Autoimmunity is lacking

van Nierop GP, Janssen M, Mitterreiter JG, van de Vijver DA, de Swart RL, Haagmans BL, Verjans GM, Hintzen RQ. Intrathecal CD4+ and CD8+ T cell responses to endogenously synthesized candidate disease-associated human autoantigens in multiple sclerosis patients. Eur J Immunol. 2015 Oct 28. doi: 10.1002/eji.201545921. [Epub ahead of print] Multiple sclerosis (MS) pathology is potentially...

Bad B cells make GM-CSF

Li et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.Sci Transl Med. 2015 Oct 21;7:310ra166. Background: B cells are not limited to producing protective antibodies; they also perform additional functions relevant to both health and disease. However, the relative contribution of functionally distinct B cell subsets in human disease, the signals that...

There is autoimmunity in MS. B means Bad!

Blauth K, Soltys J, Matschulat A, Reiter CR, Ritchie A, Baird NL, Bennett JL, Owens GP. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants. Acta Neuropathol. 2015 Oct 28. [Epub ahead of print] B cells are implicated in the aetiology of multiple sclerosis (MS). Intrathecal IgG synthesis, cerebrospinal fluid...

Will Teva and Biogen Come together for the sake of DMF, laquinimod polypill

Hund AC, Lockmann A, Schön MP. Mutually enhancing anti-inflammatory activities of dimethyl fumarate and NF-κB inhibitors – Implications for dose-sparing combination therapies. Exp Dermatol. 2015 Oct 29. doi: 10.1111/exd.12892. [Epub ahead of print] Fumaric acid esters, dimethyl fumarate (DMF) in particular, have been established for the therapy of psoriasis and, more recently, multiple...

Take two – PoliticalSpeak: Off-patent Drugs Bill – 6th November

Here’s the email I sent Chuka Umunna on 18 Oct:  Dear Mr Umunna I am contacting you about the drug re-purposing Bill to ask for your support to see it become Law. I believe it comes before the house on November 6. I attach some documents setting out the case for the Bill and please excuse me if you are already familiar with the arguments. Breakthroughs in research have meant that...

B cells assume control

Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore CS, Michel L, Althekair F, Rajasekharan S, Gommerman JL, Prat A, Fillatreau S, Bar-Or A; Canadian B cells in MS Team. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.Sci Transl Med. 2015 Oct 21;7(310):310ra166. doi: 10.1126/scitranslmed.aab4176. B cells are not limited to producing...

Repurposing Bill

Time for Activity as the Repurposing Bill is soon to be given Prime time. . But still time to get your MP to do something useful Will it get a debate or will it be binned? Few Private members Bills make it and so be prepared for the worse…  We should expect,  Pharma lobbying of Government to keep the playing field level and with many MPsappearing to take Pharma Bungs, this is...

MD I don’t understand your graphics

Sometimes you are not supposed to…. yet However they make sense if you know what they are saying Picture of the left (below) used in                                Alternative Coat of Arms of the ABN? You asked “Do you write puzzles” for those of you who have been visiting the blog for some time, can...

Lower risk of PML in Children

Hennes EM, Kornek B, Huppke P, Reindl M, Rostasy K, Berger T. Age-Dependent Seroprevalence of JCV Antibody in Children. Neuropediatrics. 2015 Oct 19. [Epub ahead of print] Progressive multifocal leukoencephalopathy (PML) is an opportunistic central nervous system infection, caused by the John Cunningham virus (JCV). PML may occur during treatment with immunosuppressive agents or monoclonal...

Now we can check what Pharma is up to. Where is the fingo trial?

On 1 January 2015 a new European Medicines Agency EMA policy on publication of clinical data entered into force. Under this policy, the Agency proactively publishes the clinical reports submitted as part of marketing-authorisation applications for human medicines.  Since 2010 the Agency has been releasing clinical-trial reports on request, under its access-to-documents policy. The...

Translate

Categories

Recent Posts

Recent Comments

Archives